Form 4: Altimmune Director Klaus Schafer Receives Stock Options

Director Klaus Schafer was granted 48,800 stock options in Altimmune, Inc. as part of the company's non-employee director compensation policy.

Summary

• Director Klaus Schafer received a grant of 48,800 stock options on May 1, 2026.
• The options have an exercise price of $2.82 per share.
• The options vest in substantially equal monthly installments over a 12-month period starting from the grant date.
• The options expire on May 1, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on the company's financial position.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Market volatility affecting the value of the underlying common stock.
• The value of the options is dependent on the company's future stock performance exceeding the $2.82 strike price.

Future Outlook

The options vest over 12 months, indicating a commitment to the company's service through May 2027.

Management Comments

• The options were granted pursuant to the Company's non-employee director compensation policy.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain board talent while aligning incentives with corporate performance.

Comparison to Industry Standards

• The 12-month vesting schedule is relatively short compared to the typical 3-4 year vesting schedules seen in broader corporate governance, though common for annual director refresh grants.
• The use of stock options for director compensation is consistent with industry peers in the small-cap biotech space.

Stakeholder Impact

• Minor dilution impact on existing shareholders upon future exercise of options.

Next Steps

• Vesting of options in monthly installments through May 2027.

Key Dates

Keywords

Altimmune, ALT, Form 4, Insider Trading, Stock Options, Director Compensation